Dublin, March 10, 2017 -- Research and Markets has announced the addition of the "Global Markets for Generic Drugs" report to their offering.
This report discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analyzed by the most important national markets. The nature and structure of the generics industry is discussed, with profiles of the leading 20+ generics companies and an update on M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.
Report Includes
- An overview of the global markets for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD
- Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021
- Examination of strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by originator companies to forestall generic competition
- Discussion of important trends by product categories and major country markets, acknowledging that Brazil, China, India, Mexico, and Russia are among the rising markets for generic activity
- Profiles of major players and leading generics companies
- A look at recent merger and acquisition activity
Key Topics Covered:
1: Introduction
- Study Goals And Objectives
- Reasons For Doing The Study
- Scope Of Report
- Market Analyses And Forecasts
- Methodology
- Intended Audience
- Information Sources
2: Summary
- Market Size And Evolution
Overview
- Recent History Of The Generics Sector
4: The New Generics Era
- The Patent Cliff
- Types Of Generics
5: Major Generic Issues
- Regulatory Environment
- Patents And IP
6: The Generics Market
- Global Pharmaceutical And Generics Market
- Market Opportunities By Product Class
7: Generics Markets And Forecasts By Country
- Americas
- Asia
- Europe
8: The Global Generics Industry
- Trends
- Structure Of The Generics Industry
- Recent M&A Activity
- Brand Company Involvement
- Profiles Of The Leading Generics Companies
- Other International Generics Companies
For more information about this report visit http://www.researchandmarkets.com/research/k6whpb/global_markets
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Generic Drugs


Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 



